Medical Aesthetics: Key Players In A Largely Untapped Market
Executive Summary
Medical aesthetics is a growing, but largely untapped biopharma niche with unique consumer marketing and doctor relationship-building strategies where key players have honed their skills for many years. Allergan's blockbuster Botox dominates, but competitors are gaining ground.
You may also be interested in...
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks
With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.
Merz Neurology Business Boosted By Xeomin Sialorrhea OK
The drug has become the only neurotoxin to be approved for excessive drooling in the US, giving Merz an advantage over rivals such as Allergan's Botox to treat a condition that affects over 600,000 adults across the Atlantic.